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Abstract
Summary The basic mechanisms by which strontium ranelate
acts on bone are still unclear. We show that an important
action of strontium salts is to block calcification in cultures
of osteoblasts, the bone-forming cells. These results suggest
that strontium treatment could have previously overlooked
effects on bone.
Introduction The basic mechanisms of action of strontium
ranelate (SrR) on bone have remained unclear. We studied
the direct actions of Sr2+ salts in functional cultures of osteo-
blasts and osteoclasts.
Methods Cultures of primary osteoblasts from rat calvariae
and osteoclast-forming mouse marrow cells were treated con-
tinuously with either SrR or strontium chloride (SrCl2).
Results Abundant, discretely mineralised ‘trabecular’ bone
structures formed in control osteoblast cultures after 14 days.
SrR at 0.01, 0.1 and 1 mM inhibited mineralisation to 59, 98
and 100 % (all p<0.001) of control values, respectively. SrCl2
at the same concentrations caused similar inhibitions. Osteo-
blast cell numbers and alkaline phosphatase activity were
unaltered. SrR dose-dependently reduced the formation of
multinucleated osteoclasts from marrow mononuclear cells
cultured on dentine for 8 days in the presence of macrophage
colony-stimulating factor (M-CSF) and receptor activator of
nuclear factor kappa B ligand (RANKL), with a 50 % inhibi-
tion occurring at 1 mM; SrCl2 was slightly less effective,
eliciting a maximal 30 % inhibition. Corresponding decreases
in total resorption pit formation were observed, suggesting
Sr2+ salts affect osteoclast formation rather than resorptive
activity.
Conclusion Our findings are consistent with the documented
physicochemical inhibitory action of Sr2+ on mineralisation
but contrast with reports that Sr2+ increases osteoblast activity
and number in vitro. Our results suggest that rather than acting
as an agent that ‘uncouples’ bone formation and resorption,
Sr2+ acts as a global inhibitor of bone cell function, with
particularly marked effects on mineralisation. The potential
effects of long-term Sr2+ on secondary mineralisation in bone
deserve investigation.
Keywords Bone cells . Calcification . In vitro . Mineral
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Introduction
The protective properties of strontium salts on bone were first
suggested in 1959 when strontium lactate was reported to
decrease bone pain in a small study of osteoporotic patients
and increase bone density radiographically [1]. Following the
report that strontium ranelate reduced vertebral fracture in
osteoporotic postmenopausal women, it has been widely used
in the treatment of osteoporosis. While the anti-fracture effi-
cacy of strontium has been well established [2, 3], the funda-
mental ways in which it acts on bone components remain
unclear.
Following the observation that dietary supplementation
with strontium chloride increased osteoid surface and de-
creased osteoclast numbers in mice [4], the notion that stron-
tium can act as a direct ‘uncoupler’ of bone turnover, enhanc-
ing bone formation and decreasing resorption, has become
well established [5–7]. Studies with cultured primary cells
indicated that strontium increased the proliferation of pre-
osteoblasts [8] and also osteoblast differentiation and
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mineralisation [7, 9, 10]. Activation of the calcium-sensing
receptor is reported to be a key pathway mediating beneficial
actions of strontium on osteoblasts, such as increased prolif-
eration [11, 12], inhibition of prostaglandin-mediated apopto-
sis [12] and increased nuclear translocation of β-catenin [13].
Strontium is also reported to increase Wnt signalling in oste-
oblasts [10] and to promote osteoblastogenesis through nucle-
ar factor kappa B (NF-κB) blockade [14]. Strontium may
reduce osteoclast activity by disrupting ruffled border forma-
tion [15] or the ‘sealing zone’ substrate contact [7]. Strontium
is additionally reported to reduce osteoclast formation [7] and
may cause osteoclast apoptosis via an NF-κB-mediated path-
way, albeit at very high concentrations [16, 17].
Strontium has also long been known to exert physicochem-
ical effects on hydroxyapatite mineral, increasing its solubility
[18–20]. Moreover, strontium causes osteomalacia in a rat
model of chronic renal failure [21] and is associated with
osteomalacia in dialysis patients [22]. In normal monkeys,
however, strontium treatment was reported to have no signif-
icant effect on bone mineral [23].
In view of the continuing debate over the actions of stron-
tium on bone and the lack of congruent studies that have
assessed the direct effects of strontium on the ultimate phys-
iological functions of osteoblasts and osteoclasts, namely
bone formation and mineralised tissue resorption, we per-
formed the present investigation. The primary aims of this
study were to determine the effects of physiologically relevant
concentrations of strontium salts on (1) the formation and
mineralisation of bony structures (‘nodules’) in primary cul-
tures of rat osteoblasts and (2) the formation and resorptive
activity of osteoclasts in mouse marrow cultures.
Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium and foetal calf serum
were purchased from (Gibco, Paisley, UK); macrophage
colony-stimulating factor (M-CSF), receptor activator of
NF-κB ligand (RANKL) and prostaglandin E2 were from
R&D Systems Europe (Abingdon, UK). Other reagents were
from Sigma-Aldrich (Poole, UK), except where otherwise
stated.
Primary osteoblast culture
Bone-forming, primary rat osteoblastic cells were obtained by
sequential enzyme digestion of excised calvarial bones from
2-day-old neonatal Sprague Dawley rats using a three-step
process, as previously described [24, 25]. Briefly, bones were
treated with 1 % trypsin in phosphate-buffered saline (PBS)
for 10 min, 0.2 % collagenase type II in Hank’s balanced salt
solution (HBSS) for 30 min, then 0.2 % collagenase type II in
HBSS for 60min. The first two digests were discarded and the
cells from the final digest resuspended in Dulbecco’s modified
essential medium supplemented with 10 % foetal calf serum
(FCS), 2 mML-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin (complete mixture
abbreviated to ‘DMEM’). Cells were cultured for 2–4 days in
a humidified atmosphere of 5 % CO2-95 % air at 37 °C in 75-
cm2 flasks until confluent. Upon confluence, cells were
subcultured into multiwell plates in ‘supplemented’ DMEM
containing dexamethasone (10 nM), β-glycerophosphate
(2 mM) and ascorbate (50 μg/ml). Cells were then cultured
for 14 days in the absence or presence of 1 μm–1 mM stron-
tium chloride or ranelate, with half medium changes every
3 days. Medium pH, pO2 and pCO2 were controlled
throughout.
At 14 days, cell layers were fixed in 2 % glutaraldehyde for
5 min and washed with 70 % ethanol prior to drying. Plates
were imaged at 2,000 dots/cm2 using a high-resolution flatbed
scanner (Perfection Photo 3200; Epson UK, Hemel Hemp-
stead, UK). Binary images of each well were analysed using
constant threshold and minimum particle levels (ImageJ soft-
ware, National Institutes of Health), allowing measurement of
the numbers bone nodules formed and their plan surface area.
Primary osteoclast culture
Osteoclast-forming marrow mononuclear cells were obtained
by flushing the long bones of two 6–8-week-old MF1 mice
using a 25-gauge needle, as previously described [26]. After
washing in PBS, marrow cells were initially cultured for 24 h
at 37 °C in 5 % CO2 in 75-cm
2 flasks in minimal essential
medium (MEM) supplemented with 10 % FCS, 2 mML-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
0.25 μg/ml amphotericin B and 100 nM prostaglandin E2
(PGE2) (abbreviated ‘supplemented MEM’) containing
2.5 ng/ml M-CSF. Non-adherent cells were collected and
resuspended at 5×106 cells/ml in supplemented MEM con-
taining 10 ng/ml M-CSF and 3 ng/ml RANKL. Two-hundred-
microlitre samples of cell suspension (106 cells) were allowed
to sediment for 24 h onto 5-mm-diameter dentine discs (ele-
phant ivory kindly donated by HM Revenue and Customs,
Heathrow Airport, UK) in 96-well trays at 37 °C to allow the
attachment of osteoclast precursors. Dentine discs were then
transferred to six-well trays containing supplemented MEM
with 10 ng/ml M-CSF and 3 ng/ml RANKL. Cells were
cultured for 8 days in 5 % CO2 with 0–1 mM of strontium
ranelate or chloride. For the final 2 days of culture, the
medium pH was reduced from 7.4 to 7.0 by addition of HCl
in order to activate resorption pit formation by mature osteo-
clasts formed.
Experiments were terminated by washing discs in PBS
followed by fixation in 2.5 % glutaraldehyde for 5 min. Discs
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were stained for tartrate-resistant acid phosphatase (TRAP)
using a leucocyte acid phosphatase kit. Osteoclasts were iden-
tified as TRAP-positive multinucleated cells; numbers of os-
teoclasts, area resorbed and, thus, activity per osteoclast were
evaluated blindly using transmitted and reflected light micros-
copy, respectively, on coded discs, as described previously
[26].
Determination of alkaline phosphatase activity
Osteoblast alkaline phosphatase activity was measured in cell
lysates after 4, 7, 10 and 14 days in culture using a colorimet-
ric kit, as previously described [24].
Cell number and viability assay
Cell numbers were measured at 3, 7, 10 and 14 days after
seeding osteoblasts at 2.5×104 cells/well into 24-well plates,
using a colorimetric kit (CytoTox 96®; Promega UK, South-
ampton, UK) which quantifies cellular lactate dehydrogenase
(LDH) activity, as previously described [27]. Briefly, cells
were lysed with 1 % Triton X-100 in water (lysis buffer,
15 μl/ml of medium) for 1 h. The culture medium supernatant
and cell lysate LDH content were measured independently
(ELx800 plate reader; BioTek International) according to the
manufacturer’s instructions, using a standard curve derived
from cells seeded between 102 and 106/well. Cell viability was
estimated as the ratio of total cellular LDH to culture medium
LDH.
Ionised Ca2+ and pH assessment
Ionised calcium and pH were measured in 300-μl medium
samples of culture medium using a blood gas analyser (Radi-
ometer 705; Radiometer, Crawley, UK).
Statistical analysis
Experimental data were analysed using one-way ANOVA
using the Bonferroni method to correct for multiple compar-
isons. Results are presented as the mean ± standard error of the
mean (SEM) for six replicates.
Results
Strontium salts inhibit bone mineralisation in vitro
Control cultures of rat osteoblasts formed abundant nodules
and trabecula-like structures of mineralised bone matrix after
14 days. Strontium ranelate (SrR) reproducibly caused a
strong, dose-dependent inhibition of mineralisation, with
near-total blockade observed at a concentration of 0.1 mM.
However, production of collagenous matrix structures ap-
peared to be unaffected even in the presence of the highest
concentration of strontium ranelate used (1 mM) (Fig. 1). At
concentrations of 0.01, 0.1 and 1 mM, SrR elicited 59, 98 and
100 % inhibitions of mineralisation of control values, respec-
tively. Strontium chloride (SrCl2) also inhibited mineralisation
strongly, causing 34, 95 and 100 % reductions at the same
concentrations (Fig. 2a). Strontium salts caused a correspond-
ing increase in the retention of ionised calcium in the osteo-
blast culture medium. After 14 days of treatment with 1 mM
SrR or SrCl2, the measured calcium concentration in the
culture medium was the same as that in the medium from
undifferentiated day 3 cultures in which the control osteo-
blasts had yet to begin mineralising (i.e. about 1 mM). Medi-
um pH in strontium-treated cultures remained close to the
control value (Fig. 2b).
A moderate reduction of osteoblast alkaline phosphatase
(ALP) activity was observed in 14-day cultures treated with
SrCl2; smaller decreases were also seen in SrR-treated cultures
(Fig. 3a). In parallel, strontium salts caused increases in lactate
dehydrogenase release from cells, an index of cell morbidity/
mortality, although estimated cell numbers were not signifi-
cantly affected (Fig. 3b).
Strontium salts inhibit osteoclast numbers and resorption pit
formation
Continuous treatment with strontium salts caused reductions
of up to about 50 % in the total surface area of resorption pits
and in the numbers of multinucleated osteoclasts present on
ivory discs in 8-day cultures of mousemarrow cells. However,
the area resorbed by individual osteoclasts was not signifi-
cantly reduced (Figs. 4 and 5).
Discussion
Strontium ranelate has been regarded as an anti-osteoporotic
drug that can shift the balance between bone resorption and
bone formation towards the latter. However, the mechanisms
by which strontium exerts its effects on bone have remained
relatively unclear [28]. Our results clearly demonstrate that
strontium salts have two direct effects on bone cell function
in vitro. Their major action is to cause potent inhibition of
mineral deposition in bone-forming cultures of primary oste-
oblasts. Secondly, strontium salts cause moderate reductions
in osteoclast numbers and, thus, resorption pit formation in
mouse marrow cultures on dentine surfaces.
Mineralisation in bone-forming osteoblast cultures was
dose-dependently reduced by strontium salts, with partial or
near-complete inhibition at 0.01 and 0.1 mM, respectively.
Osteoporos Int
The strontium-treated cultures showed a striking and corre-
sponding increase in the presence of unmineralised matrix
nodules. The observed inhibition of mineralisation by
strontium salts at micromolar concentrations in primary rat
osteoblast cultures is in broad agreement with the earlier
findings of Verberckmoes et al. [29]. We also failed to observe
Fig. 1 Strontium ranelate (SrR)
blocks bone matrix mineralisation
in 14-day primary cultures of rat
osteoblasts. Upper row images
are reflected light scans of
unstained cell wells; mineralised
bone nodules appear as white
features; scale bar=0.5 cm.
Lower row images are
corresponding phase contrast
(transmitted light) micrographs of
unstained cell layers; mineralised
bone nodules appear as black
features, and unmineralised
collagenous matrix is white-grey;
scale bar=0.5 mm
Fig. 2 a Dose-dependent
inhibition of mineralised bone
formation in 14-day rat osteoblast
cultures by strontium salts.
Strontium ranelate (SrR) caused
near-total blockade at
concentrations ≥0.1 mM;
strontium chloride (SrCl2)
completely blocked
mineralisation at a concentration
of 1 mM. b Strontium salts caused
a corresponding increase in the
retention of ionised calcium in the
culture medium of bone-forming
osteoblasts; the measured
concentration of ionised Ca2+ in
the culture medium at day 3 (i.e.
before onset of osteoblast
differentiation and mineral
deposition) was 1.03 mM.
Culture medium pH remained
within 0.01 unit of the control
value. pH was corrected for CO2
concentration. Data are means ±
SEM for six replicate
determinations; ***p<0.001,
significantly different from
control
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any clear-cut effect of strontium on osteoblast numbers (al-
though an apparent reduction in cell viability was noted in
strontium-treated cultures). In contrast, we found a modest
inhibitory effect of strontium chloride at submillimolar con-
centrations on osteoblast alkaline phosphatase activity. These
findings are at variance with those of several other studies on
the action of strontium ranelate in calvarial osteoblast cultures.
Acute stimulation of proliferation of rat osteoblasts was de-
scribed following exposure to high concentrations (1–5 mM)
of SrR [8, 11]. Increased calcification and expression of
Fig. 3 a Effect of strontium salts
on alkaline phosphatase (ALP)
activity in 14-day rat osteoblast
cultures: modest inhibition by
SrCl2. b Strontium salts were also
associated with moderate
decreases in cell viability,
assessed as lactate dehydrogenase
activity, although cell numbers
were not affected. Data are means
± SEM for six replicate
determinations; *p<0.05;
**p<0.01; ***p<0.001,
significantly different from
control
Fig. 4 Strontium ranelate causes
a moderate inhibition of numbers
of multinucleated osteoclasts
observed in mouse marrow
mononuclear cells cultured for
8 days on ivory discs withM-CSF
and RANKL. TRAP-stained
preparation; resorption pits are
visible as tan areas associated
with osteoclasts. Scale bar=
100 μm
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alkaline phosphatase mRNA were reported for mouse osteo-
blasts treated chronically with 0.1–1 mM strontium ranelate
[7]. In the MC3T3-E1 cell line, however, strontium ranelate
treatment increased the strontium content of deposited mineral
but failed to increase calcification [30]. The discrepancies
between the above findings could, to some extent, be
accounted for by significant differences in osteoblast culture
methods. The key advantage of the culture system employed
in the present study is the formation of abundant bony struc-
tures that resemble trabeculae, with clearly distinguished
mineralised and non-mineralised components [24, 25].
Our study showed that strontium ranelate was a significant-
ly more effective inhibitor of mineralisation on a molar basis
than strontium chloride. This discrepancy in potency may well
be due to the differing stoichiometry of these two strontium
salts. Ranelate chelates two strontium ions per molecule,
whereas the chloride salt has only a single strontium ion.
However, it is possible that the ranelate component of stron-
tium ranelate may also have an independent calcium ion-
chelating action that could affect mineralisation. The inhibi-
tion of mineralisation in strontium-treated osteoblast cultures
was reflected in increased retention of ionised calcium in the
culture medium. It should be noted that this calcium retention
was of a lower relative magnitude than the degree of inhibition
of mineralisation. This apparent inconsistency is explained by
the changes of culturemedium that weremade every 3–4 days.
Studies by Verberckmoes et al. [31], using mineralising cul-
tures of osteoblast-like UMR-106 cells and synthetic calcium
hydroxyapatite doped with increasing concentrations of stron-
tium, have suggested that strontium inhibits mineralisation via
two physicochemical effects: first, direct inhibition of crystal
growth and, secondly, increased solubility of calcium
hydroxyapatite.
The action of strontium salts on osteoclast function was
much less marked than on osteoblasts and mineralisation. At
the highest concentration tested (1mM), strontium caused 33–
50 % reductions in both osteoclast numbers and resorption pit
formation, suggesting that it had little or no direct effect on
osteoclast activity (i.e. resorption pit formation). The reduced
numbers of osteoclasts observed in strontium-treated cultures
could be due either to reduced formation or reduced survival
or both. Previous studies have noted reductions in osteoclast
numbers in cultures treated with strontium salts at concentra-
tions up to 24 mM [7, 17]; these very high concentrations are
well outside the in vivo range, however.
The strontium concentrations used in the present study
spanned the levels measured in the blood of treated individ-
uals (0.02 mM) [32]. However, there is a clear discrepancy
between our in vitro findings and the results of the major
clinical trials of strontium ranelate, which showed decreased
fracture risk associated with increases in bone mineral density
of between 7.2 and 14.4% after prolonged treatment [2, 33]. It
should be noted, though, that a significant component of the
increased bone mineral density measured in strontium-treated
patients could be due to the incorporation of strontium, which
has more than twice the atomic mass of calcium; a 1 % molar
concentration of strontium has been shown to cause a 10 %
overestimation of BMD [34]. In contrast to the reported
Fig. 5 a Strontium salts cause a moderate inhibition of resorption pit
formation by osteoclasts generated in 8-day cultures of mouse marrow
cells on ivory discs. b Strontium salts were associated with corresponding
decreases in numbers of multinucleated, TRAP-stained osteoclasts. c The
resorptive activity of individual osteoclasts was not affected by strontium
salts. Data are means ± SEM for eight replicate determinations; *p<0.05;
***p<0.001, significantly different from control
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increases in bone mineral density, strontium-induced osteo-
malacia has been described in rats with chronic renal failure
[21, 35]. Strontium levels in blood and bone have been linked
to osteomalacia in human patients undergoing haemodialysis
in some studies [22, 36].
The key limitation of our study is that it was conducted
in vitro using rodent cells. However, cell or organ cultures
represent the only practicable way to study the direct effects of
strontium on bone cells, free of the confounding influences
present in vivo. The use of rodent osteoblasts was necessitated
because primary human osteoblasts (at least from adults) have
not been shown to be capable of true bone formation in vitro.
Clearly, caution is needed when relating tissue culture results
to the in vivo situation. Nevertheless, our findings do suggest
a number of testable ideas. The first is that long-term stron-
tium treatment might act to reduce fracture risk because it
could reduce the secondary hypermineralisation that occurs in
low-turnover bone, thus decreasing stiffness and reducing
brittleness [37]. Similarly, strontium treatment, which is re-
ported to be protective against some forms of osteoarthritis
[38, 39], might act to reduce secondary mineralisation of
subchondral bone, making it less stiff. It is also conceivable
that strontium could affect the progression of the tidemark
zone of mineralisation in articular cartilage. A further possi-
bility is that strontium treatment might act to modulate the
i n f i l l i ng o f o s t eocy t e l a cunae r e su l t i ng f rom
hypermineralisation [40].
Widespread use of strontium ranelate has now been
discontinued in most countries, following recent recommen-
dations concerning its potential cardiovascular risk, although
this remains somewhat controversial [41]. It is nonetheless
important that the mechanisms of action of strontium on bone
are better understood—not only for patients already treated
but also because new therapeutic directions could be sug-
gested, particularly with regard to the control of
mineralisation.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
References
1. McCaslin FE, Janes JM (1959) The effect of strontium lactate in the
treatment of osteoporosis. Proc Staff Meetings Mayo Clin 34:329–
334
2. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J,
Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemaere S,
Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate
reduces the risk of nonvertebral fractures in postmenopausal women
with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS)
study. J Clin Endocrinol Metab 90:2816–2822
3. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devodelaer JP
(2008) Strontium ranelate reduces the risk of vertebral fracture in
young postmenopausal women with severe osteoporosis. Ann
Rheum Dis 67:1736–1738
4. Marie PJ, Hott M (1986) Short-term effects of fluoride and strontium
on bone formation and resorption in the mouse. Metabolism 35:547–
551
5. Marie PJ, Hott M,Modrowski D, de Pollak C, Guillemain J, Deloffre
P, Tsouderos Y (1993) An uncoupling agent containing strontium
prevents bone loss by depressing bone resorption and maintaining
bone formation in estrogen-deficient rats. J BoneMin Res 3:607–615
6. Ammann P (2006) Strontium ranelate: a physiological approach for
an improved bone quality. Bone 38:15–18
7. Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of
strontium ranelate: stimulation of osteoblast differentiation and inhi-
bition of osteoclast formation and resorption in vitro. Bone 42:129–
138
8. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The
divalent strontium salt S12911 enhances bone cell replication and
bone formation in vitro. Bone 18:517–523
9. Marie PJ (2005) Strontium ranelate: a novel mode of action optimiz-
ing bone formation and resorption. Osteoporos Int 16:S7–S10
10. Yang F, Yang D, Tu J, Zheng Q, Cai L, Wang L (2011) Strontium
enhances osteogenic differentiation of mesenchymal stem cells and
in vivo bone formation by activating Wnt/catenin signalling. Stem
Cells 29:981–991
11. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM (2007) The
calcium-sensing receptor (CaR) is involved in strontium ranelate-
induced osteoblast proliferation. Biochem Pharmacol 74:438–447
12. Fromigue O, Hay E, Barbara A, Petrel C, Traiffort E, Ruat M, Marie
PJ (2009) Calcium sensing receptor-dependent and receptor-
independent activation of osteoblast replication and survival by
strontium ranelate. J Cell Mol Med 13:2189–2199
13. Rybchyn MS, Slater M, Conigrave AD, Mason RS (2011) An Akt-
dependent increase in canonical Wnt signaling and a decrease in
sclerostin protein levels are involved in strontium ranelate-induced
osteogenic effects in human osteoblasts. J Biol Chem 286:23771–
23779
14. Yamaguchi M, Weitzmann MN (2012) The intact strontium ranelate
complex stimulates osteoblastogenesis and suppresses osteoclasto-
genesis by antagonizing NF-κB activation. Mol Cell Biochem 359:
399–407
15. Takahashi N, Sasaki T, Tsouderos Y, Suda T (2003) S 12911-2
inhibits osteoclastic bone resorption in vitro. J Bone Min Res 18:
1082–1088
16. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel
A, Kamel S, Terwilliger EF, Brown EM, Brazier M (2008) The
calcium-sensing receptor is involved in strontium ranelate-induced
osteoclast apoptosis: new insights into the associated signalling path-
ways. J Biol Chem 284:575–584
17. Caudrillier A, Hurtel-Lemaire AS, Wattel A, Cournarie F, Godin C,
Petit L, Petit JP, Terwilliger E, Kamel S, Brown EM, Mentaverri R,
Brazier M (2010) Strontium ranelate decreases receptor activator of
nuclear factor-B ligand-induced osteoclastic differentiation in vitro:
involvement of the calcium-sensing receptor. Mol Pharm 78:569–
576
18. GrynpasM (1993) Age and diseases-related changes in themineral of
bone. Calcif Tissue Int 53:S57–64
19. Christoffersen J, Christoffersen MR, Kolthoff N, Barenholdt O
(1997) Effects of strontium ions on growth and dissolution of hy-
droxyapatite and on bone mineral detection. Bone 20:47–54
20. Pan HB, Li ZY, Lam WM, Wong JC, Darvell BW, Luk KDK, Lu
WW (2009) Solubility of strontium-substituted apatite by solid titra-
tion. Acta Bio 5:1678–1685
Osteoporos Int
21. Schrooten I, Cabrera W, Goodman WG, Dauwe S, Lamberts LV,
Marynissen R, Dorrine W, De Broe ME, D’Haese PC (1998)
Strontium causes osteomalacia in chronic renal failure rats. Kidney
Int 54:448–456
22. D’Haese PC, Schrooten I, GoodmanWG,CabreraWE, Lamberts LV,
Elseviers MM, Couttenye MM, De Broe ME (2000) Increased bone
strontium levels in haemodialysis patients with osteomalacia. Kidney
Int 57:1107–1114
23. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y,
Allain P, Tsouderos Y, Meunier PJ (1996) Strontium distribution and
interactions with bone mineral in monkey iliac bone after strontium
salt (S 12911). J Bone Miner Res 11:1302–1311
24. Orriss IR, Utting JC, Brandao-Burch A, Colston K, Grubb BR,
Burnstock G, Arnett TR (2007) Extracellular nucleotides block bone
mineralization in vitro: evidence for dual inhibitory mechanisms
involving both P2Y2 receptors and pyrophosphate. Endocrinology
148:4208–4216
25. Orriss IR, Taylor SE, Arnett TR (2012) Rat osteoblast cultures.
Methods Mol Biol 816:31–41
26. Patel JJ, Utting JC,KeyML,Orriss IR, Taylor SE,Whatling P, Arnett TR
(2012) Hypothermia inhibits osteoblast differentiation and bone forma-
tion but stimulates osteoclastogenesis. Exp Cell Res 318:2237–2244
27. Orriss IR, Key ML, Hajjawi MO, Arnett TR (2013) Extracellular
ATP released by osteoblasts is a key local inhibitor of bone
mineralisation. PLoS One 8(7):e69057
28. Karsdal MA, Bay-Jensen AC, Lories RJ, Abramson S, Spector T,
Pastoureau P, Christiansen C, Attur M, Henriksen K, Goldring SR,
Kraus V (2014) The coupling of bone and cartilage turnover in
osteoarthritis: opportunities for bone antiresorptives and anabolics
as potential treatments? Ann Rheum Dis 73:336–348
29. Verberckmoes SC, De Broe ME, D’Haese PC (2003) Dose-
dependent effects of strontium on osteoblast function and minerali-
zation. Kidney Int 64:534–543
30. Barbara A, Delannoy P, Denis BG, Marie PJ (2004) Normal matrix
mineralization induced by strontium ranelate in MC3T3-E1 osteo-
genic cells. Metabolism 53:532–537
31. Verberckmoes SC, Behets GJ, Oste L, Bervoets AR, Lamberts
LV, Drakopoulos M, Somogyi A, Cool P, Dorrine W, De Broe
ME, D’Haese PC (2004) Effects of strontium on the physico-
chemical characteristics of hydroxyapatite. Calcif Tissue Int
75:405–415
32. Marie PJ (2008) Effective doses for strontium ranelate. Osteoporos
Int 19:1813
33. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector
TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R,
Genant HK, Reginster JY (2004) The effects of strontium ranelate on
the risk of vertebral fracture in women with postmenopausal osteo-
porosis. N Engl J Med 350:459–468
34. Blake GM, Fogelman I (2007) Effect of bone strontium on BMD
measurements. J Clin Densitom 10:34–38
35. Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR,
Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G,
Goodman WG, De Broe ME, D’Haese PC (2003) Dose-
dependent effects of strontium on bone of chronic renal
failure rats. Kidney Int 63:927–935
36. Schrooten I, Elseviers MM, Lamberts LV, De Broe ME,
D’Haese PC (1999) Increased serum strontium levels in dial-
ysis patients: an epidemiological survey. Kidney Int 56:1886–
1892
37. Zioupos P, Currey JD, Casinos A (2000) Exploring the effects of
hypermineralisation in bone tissue by using an extreme biological
example. Connect Tissue Res 41:229–248
38. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R,
Chevalier X, Christiansen C, Genant H, Navarro F, Nasonov E,
Sambrook PN, Spector TD, Cooper C (2013) Efficacy and safety
of strontium ranelate in the treatment of knee osteoarthritis: results of
a double-blind, randomised placebo-controlled trial. Ann Rheum Dis
72:179–186
39. Bruyere O, Delferriere D, Roux C, Wark JD, Spector T, Devogelaer
JP (2008) Effects of strontium ranelate on spinal osteoarthritis pro-
gression. Ann Rheum Dis 67:335–9
40. Atkins GJ, Findlay DM (2012) Osteocyte regulation of bone mineral:
a little give and take. Osteoporos Int 23:2067–2079
41. Donneau AF, Reginster JY (2014) Cardiovascular safety of strontium
ranelate: real-life assessment in clinical practice. Osteoporos Int 25:
397–398
Osteoporos Int
